We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Henry Schein (HSIC) Inks Distribution Agreement with Terason
Read MoreHide Full Article
Henry Schein Medical, a subsidiary of Henry Schein, Inc. (HSIC - Free Report) , announced an exclusive distribution agreement with Terason to distribute the latter’s uSmart 3200T NexGen. This development remains a part of Henry Schein Medical’s Emergency Medical Services ("EMS") business.
Terason a division of Teratech Corporation is a manufacturer of portable ultrasound machine. uSmart 3200T is a portable ultrasound device that allows emergency responders to carry out exams in emergency medical transport vehicles and aircrafts. This reduces the need to speculate for EMS professionals. uSmart 3200T NexGen is a portable light-weight ultrasound tablet, easy to transport and operate.
The Terason uSmart 3200T features many advanced features including customized presets, fast boot-up, grab-and-go portability and Wi-Fi capabilities. Responders can recognize issues at the point-of-care, during transportation and also alert emergency room staff of important vitals with uSmart 3200T. According to the company, accessing patient's vitals will help emergency responders make more informed decisions on treatment. Also, it helps emergency room staff to prepare ahead of the patient’s arrival.
Henry Schein is consistently working toward boosting its Medical segment. Notably, worldwide Medical revenues rose 6.1% year over year in the last reported second quarter. Henry Schein Medical recently inked an agreement with Cerebral Assessment Systems (“CAS”) to distribute Cognivue. This is the first computerized cognitive assessment screening device cleared by the FDA for the detection of early signs of dementia. Moreover, Henry Schein announced a partnership with Simplifeye to create a mobile platform for health care providers who use its practice management and electronic health record software — MicroMD.
According to a report by Markets and Markets, the ultrasound market is expected to reach a value of $6.86 billion by 2021, at a CAGR of 5.2% during 2016 to 2021. Considering the substantial potential of the market, we believe the latest development is a strategic one.
Over the past year, Henry Schein has underperformed the broader industry. The stock has gained 6.8%, compared with the 10.3% gain of the broader industry.
Estimate Revision Trend
The estimate revision trend has been favorable for the company. For the current quarter, two estimates moved north compared with five movements in the opposite direction over the last two months. As a result, the Zacks Consensus Estimate for current-quarter earnings per share has increased to 90 cents from 89 cents.
Abbott has a long-term expected earnings growth rate of 10.7%. The stock rallied roughly 32.7% over the last year.
IDEXX Laboratories has a long-term expected earnings growth rate of 19.8%. The stock gained 40.9% last year.
Thermo Fisher has a long-term expected earnings growth rate of 11.7%. The stock gained 26.1% last year.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Image: Bigstock
Henry Schein (HSIC) Inks Distribution Agreement with Terason
Henry Schein Medical, a subsidiary of Henry Schein, Inc. (HSIC - Free Report) , announced an exclusive distribution agreement with Terason to distribute the latter’s uSmart 3200T NexGen. This development remains a part of Henry Schein Medical’s Emergency Medical Services ("EMS") business.
Terason a division of Teratech Corporation is a manufacturer of portable ultrasound machine. uSmart 3200T is a portable ultrasound device that allows emergency responders to carry out exams in emergency medical transport vehicles and aircrafts. This reduces the need to speculate for EMS professionals. uSmart 3200T NexGen is a portable light-weight ultrasound tablet, easy to transport and operate.
The Terason uSmart 3200T features many advanced features including customized presets, fast boot-up, grab-and-go portability and Wi-Fi capabilities. Responders can recognize issues at the point-of-care, during transportation and also alert emergency room staff of important vitals with uSmart 3200T. According to the company, accessing patient's vitals will help emergency responders make more informed decisions on treatment. Also, it helps emergency room staff to prepare ahead of the patient’s arrival.
Henry Schein is consistently working toward boosting its Medical segment. Notably, worldwide Medical revenues rose 6.1% year over year in the last reported second quarter. Henry Schein Medical recently inked an agreement with Cerebral Assessment Systems (“CAS”) to distribute Cognivue. This is the first computerized cognitive assessment screening device cleared by the FDA for the detection of early signs of dementia. Moreover, Henry Schein announced a partnership with Simplifeye to create a mobile platform for health care providers who use its practice management and electronic health record software — MicroMD.
According to a report by Markets and Markets, the ultrasound market is expected to reach a value of $6.86 billion by 2021, at a CAGR of 5.2% during 2016 to 2021. Considering the substantial potential of the market, we believe the latest development is a strategic one.
Over the past year, Henry Schein has underperformed the broader industry. The stock has gained 6.8%, compared with the 10.3% gain of the broader industry.
Estimate Revision Trend
The estimate revision trend has been favorable for the company. For the current quarter, two estimates moved north compared with five movements in the opposite direction over the last two months. As a result, the Zacks Consensus Estimate for current-quarter earnings per share has increased to 90 cents from 89 cents.
Zacks Rank & Key Picks
Henry Schein has a Zacks Rank #3 (Hold). A few better-ranked stocks in the medical sector are Abbott (ABT - Free Report) , IDEXX Laboratories, Inc. (IDXX - Free Report) and Thermo Fisher Scientific Inc. (TMO - Free Report) . Abbott, IDEXX Laboratories and Thermo Fisher carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Abbott has a long-term expected earnings growth rate of 10.7%. The stock rallied roughly 32.7% over the last year.
IDEXX Laboratories has a long-term expected earnings growth rate of 19.8%. The stock gained 40.9% last year.
Thermo Fisher has a long-term expected earnings growth rate of 11.7%. The stock gained 26.1% last year.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>